Mega Lifesciences Public Company Limited (MEGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA) has a cash flow conversion efficiency ratio of 0.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (฿461.26 Million ≈ $14.38 Million USD) by net assets (฿9.95 Billion ≈ $310.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mega Lifesciences Public Company Limited - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MEGA liabilities breakdown for a breakdown of total debt and financial obligations.
Mega Lifesciences Public Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Cosmos Chemical Co Ltd
SHE:300856
|
0.037x |
|
Manchester United Ltd
F:MUF
|
-0.007x |
|
Burke & Herbert Financial Services Corp. Common Stock
NASDAQ:BHRB
|
0.046x |
|
Celebi Hava Servisi AS
IS:CLEBI
|
-0.086x |
|
Agesa Hayat ve Emeklilik AS
IS:AGESA
|
0.086x |
|
Daheng New Epoch Technology Inc
SHG:600288
|
0.026x |
|
Dios Fastigheter AB
ST:DIOS
|
0.026x |
|
BlackRock Credit Allocation Income Trust
NYSE:BTZ
|
0.039x |
Annual Cash Flow Conversion Efficiency for Mega Lifesciences Public Company Limited (2011–2024)
The table below shows the annual cash flow conversion efficiency of Mega Lifesciences Public Company Limited from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Mega Lifesciences Public Company Limited (MEGA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ฿9.88 Billion ≈ $307.85 Million |
฿2.40 Billion ≈ $74.85 Million |
0.243x | +17.40% |
| 2023-12-31 | ฿9.30 Billion ≈ $289.94 Million |
฿1.93 Billion ≈ $60.05 Million |
0.207x | -8.96% |
| 2022-12-31 | ฿8.78 Billion ≈ $273.56 Million |
฿2.00 Billion ≈ $62.23 Million |
0.227x | -33.05% |
| 2021-12-31 | ฿8.03 Billion ≈ $250.14 Million |
฿2.73 Billion ≈ $84.99 Million |
0.340x | +45.53% |
| 2020-12-31 | ฿6.98 Billion ≈ $217.53 Million |
฿1.63 Billion ≈ $50.79 Million |
0.233x | -3.57% |
| 2019-12-31 | ฿6.18 Billion ≈ $192.47 Million |
฿1.50 Billion ≈ $46.60 Million |
0.242x | +50.75% |
| 2018-12-31 | ฿5.72 Billion ≈ $178.42 Million |
฿919.36 Million ≈ $28.66 Million |
0.161x | -9.14% |
| 2017-12-31 | ฿5.24 Billion ≈ $163.46 Million |
฿927.00 Million ≈ $28.89 Million |
0.177x | -34.37% |
| 2016-12-31 | ฿4.68 Billion ≈ $145.87 Million |
฿1.26 Billion ≈ $39.29 Million |
0.269x | +91.67% |
| 2015-12-31 | ฿4.33 Billion ≈ $135.11 Million |
฿609.12 Million ≈ $18.99 Million |
0.141x | -8.98% |
| 2014-12-31 | ฿3.98 Billion ≈ $124.00 Million |
฿614.22 Million ≈ $19.14 Million |
0.154x | +22.40% |
| 2013-12-31 | ฿3.69 Billion ≈ $115.09 Million |
฿465.77 Million ≈ $14.52 Million |
0.126x | -40.02% |
| 2012-12-31 | ฿1.63 Billion ≈ $50.69 Million |
฿342.02 Million ≈ $10.66 Million |
0.210x | +3.97% |
| 2011-12-31 | ฿1.32 Billion ≈ $41.09 Million |
฿266.67 Million ≈ $8.31 Million |
0.202x | -- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more